211 related articles for article (PubMed ID: 25491191)
1. Acceptance and adherence to chemoprevention among women at increased risk of breast cancer.
Roetzheim RG; Lee JH; Fulp W; Matos Gomez E; Clayton E; Tollin S; Khakpour N; Laronga C; Lee MC; Kiluk JV
Breast; 2015 Feb; 24(1):51-6. PubMed ID: 25491191
[TBL] [Abstract][Full Text] [Related]
2. Breast Cancer Chemoprevention among High-risk Women and those with Ductal Carcinoma In Situ.
Reimers LL; Sivasubramanian PS; Hershman D; Terry MB; Greenlee H; Campbell J; Kalinsky K; Maurer M; Jayasena R; Sandoval R; Alvarez M; Crew KD
Breast J; 2015; 21(4):377-86. PubMed ID: 25879521
[TBL] [Abstract][Full Text] [Related]
3. Chemoprevention acceptance and adherence in women with high-risk breast lesions.
Roche CA; Tang R; Coopey SB; Hughes KS
Breast J; 2019 Mar; 25(2):190-195. PubMed ID: 29785770
[TBL] [Abstract][Full Text] [Related]
4. The role of chemoprevention in modifying the risk of breast cancer in women with atypical breast lesions.
Coopey SB; Mazzola E; Buckley JM; Sharko J; Belli AK; Kim EM; Polubriaginof F; Parmigiani G; Garber JE; Smith BL; Gadd MA; Specht MC; Guidi AJ; Roche CA; Hughes KS
Breast Cancer Res Treat; 2012 Dec; 136(3):627-33. PubMed ID: 23117858
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of tamoxifen chemoprevention for breast cancer in very high-risk women: a cost-effectiveness analysis.
Hershman D; Sundararajan V; Jacobson JS; Heitjan DF; Neugut AI; Grann VR
J Clin Oncol; 2002 Jan; 20(1):9-16. PubMed ID: 11773148
[TBL] [Abstract][Full Text] [Related]
6. Breast carcinoma chemoprevention in the community setting. Estimating risks and benefits.
Brewster AM; Christo DK; Lai H; Helzlsouer K
Cancer; 2005 Mar; 103(6):1147-53. PubMed ID: 15674856
[TBL] [Abstract][Full Text] [Related]
7. Women's views on chemoprevention of breast cancer: qualitative study.
Heisey R; Pimlott N; Clemons M; Cummings S; Drummond N
Can Fam Physician; 2006 May; 52(5):624-5. PubMed ID: 17327893
[TBL] [Abstract][Full Text] [Related]
8. Uptake of exemestane chemoprevention in postmenopausal women at increased risk for breast cancer.
Aktas B; Sorkin M; Pusztai L; Hofstatter EW
Eur J Cancer Prev; 2016 Jan; 25(1):3-8. PubMed ID: 25642790
[TBL] [Abstract][Full Text] [Related]
9. Acceptability and adherence in a chemoprevention trial among women at increased risk for breast cancer attending the Modena Familial Breast and Ovarian Cancer Center (Italy).
Razzaboni E; Toss A; Cortesi L; Marchi I; Sebastiani F; De Matteis E; Federico M
Breast J; 2013; 19(1):10-21. PubMed ID: 23252601
[TBL] [Abstract][Full Text] [Related]
10. Should tamoxifen be used in breast cancer prevention?
Kramer R; Brown P
Drug Saf; 2004; 27(13):979-89. PubMed ID: 15471505
[TBL] [Abstract][Full Text] [Related]
11. Exemestane for breast-cancer prevention in postmenopausal women.
Goss PE; Ingle JN; Alés-Martínez JE; Cheung AM; Chlebowski RT; Wactawski-Wende J; McTiernan A; Robbins J; Johnson KC; Martin LW; Winquist E; Sarto GE; Garber JE; Fabian CJ; Pujol P; Maunsell E; Farmer P; Gelmon KA; Tu D; Richardson H;
N Engl J Med; 2011 Jun; 364(25):2381-91. PubMed ID: 21639806
[TBL] [Abstract][Full Text] [Related]
12. Chemoprevention Uptake among Women with Atypical Hyperplasia and Lobular and Ductal Carcinoma
Trivedi MS; Coe AM; Vanegas A; Kukafka R; Crew KD
Cancer Prev Res (Phila); 2017 Aug; 10(8):434-441. PubMed ID: 28611039
[TBL] [Abstract][Full Text] [Related]
13. Novel translational model for breast cancer chemoprevention study: accrual to a presurgical intervention with tamoxifen and N-[4-hydroxyphenyl] retinamide.
Singletary E; Lieberman R; Atkinson N; Sneige N; Sahin A; Tolley S; Colchin M; Bevers T; Stelling C; Fornage B; Fritsche H; Hittelman W; Kelloff G; Lippman SM
Cancer Epidemiol Biomarkers Prev; 2000 Oct; 9(10):1087-90. PubMed ID: 11045792
[TBL] [Abstract][Full Text] [Related]
14. Acceptance of tamoxifen chemoprevention by physicians and women at risk.
Tchou J; Hou N; Rademaker A; Jordan VC; Morrow M
Cancer; 2004 May; 100(9):1800-6. PubMed ID: 15112259
[TBL] [Abstract][Full Text] [Related]
15. Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction.
Melnikow J; Paterniti D; Azari R; Kuenneth C; Birch S; Kuppermann M; Nuovo J; Keyzer J; Henderson S
Cancer; 2005 May; 103(10):1996-2005. PubMed ID: 15825209
[TBL] [Abstract][Full Text] [Related]
16. Risk-benefit profiles of women using tamoxifen for chemoprevention.
Nichols HB; DeRoo LA; Scharf DR; Sandler DP
J Natl Cancer Inst; 2015 Jan; 107(1):354. PubMed ID: 25475563
[TBL] [Abstract][Full Text] [Related]
17. Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: a decision analysis.
Grann VR; Jacobson JS; Whang W; Hershman D; Heitjan DF; Antman KH; Neugut AI
Cancer J Sci Am; 2000; 6(1):13-20. PubMed ID: 10696733
[TBL] [Abstract][Full Text] [Related]
18. Lobular Carcinoma in Situ: A 29-Year Longitudinal Experience Evaluating Clinicopathologic Features and Breast Cancer Risk.
King TA; Pilewskie M; Muhsen S; Patil S; Mautner SK; Park A; Oskar S; Guerini-Rocco E; Boafo C; Gooch JC; De Brot M; Reis-Filho JS; Morrogh M; Andrade VP; Sakr RA; Morrow M
J Clin Oncol; 2015 Nov; 33(33):3945-52. PubMed ID: 26371145
[TBL] [Abstract][Full Text] [Related]
19. Chemoprevention of breast cancer.
Dalton RR; Kallab AM
South Med J; 2001 Jan; 94(1):7-15. PubMed ID: 11213947
[TBL] [Abstract][Full Text] [Related]
20. Budget impact analysis of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan.
Kondo M; Hoshi SL; Toi M
Jpn J Clin Oncol; 2009 Nov; 39(11):767-70. PubMed ID: 19656807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
